Literature DB >> 15454170

Cardiotropic viruses in the myocardium of children with end-stage heart disease.

Paola Francalanci1, Jamie L Chance, Matteo Vatta, Shinawe Jimenez, Hua Li, Jeffrey A Towbin, Neil E Bowles.   

Abstract

BACKGROUND: Transplantation has become a lifesaving procedure for children with end-stage heart failure. The long-term outcome for children who undergo transplantation has been of considerable interest, but the causes of graft failure and death are largely unknown, and the role of pre-transplant viral infection is unclear.
METHODS: Myocardial samples from 80 explanted hearts from children with end-stage heart disease caused by congenital heart disease (CHD), cardiomyopathy, or chronic rejection were analyzed using polymerase chain reaction and reverse-transcriptase polymerase chain reaction for cardiotropic viruses using virus-specific primers. We used immunohistochemical analysis of cytoskeletal proteins to evaluate myocyte architecture.
RESULTS: We identified parvoviral genomes in 6 patients (3 with CHD and 3 with cardiomyopathy). We detected no other viruses. Immunohistochemistry showed normal staining for key components of the cytoskeleton/sarcolemma, sarcomere, and nuclear membrane in the 6 virus-positive samples. The clinical outcome of these children was worse (4 long-term survivors, but 2 deaths) than for individuals without the genome.
CONCLUSIONS: Detecting viruses within the myocardium at the point of end-stage heart failure is not common, regardless of the primary pathology. However, the presence of viruses may result in poor outcome for the patient.

Entities:  

Mesh:

Year:  2004        PMID: 15454170     DOI: 10.1016/j.healun.2003.08.015

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  6 in total

1.  Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients.

Authors:  John P Breinholt; Mousumi Moulik; William J Dreyer; Susan W Denfield; Jeffrey J Kim; John L Jefferies; Joseph W Rossano; Corey M Gates; Sarah K Clunie; Karla R Bowles; Debra L Kearney; Neil E Bowles; Jeffrey A Towbin
Journal:  J Heart Lung Transplant       Date:  2010-04-24       Impact factor: 10.247

2.  Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure.

Authors:  Garrick C Stewart; Javier Lopez-Molina; Raju V S R K Gottumukkala; Gregg F Rosner; Mary S Anello; Jonathan L Hecht; Gayle L Winters; Robert F Padera; Kenneth L Baughman; Myra A Lipes
Journal:  Circ Heart Fail       Date:  2010-11-19       Impact factor: 8.790

3.  Early predictors of survival to and after heart transplantation in children with dilated cardiomyopathy.

Authors:  Biagio A Pietra; Paul F Kantor; Heather L Bartlett; Clifford Chin; Charles E Canter; Ranae L Larsen; R Erik Edens; Steven D Colan; Jeffrey A Towbin; Steven E Lipshultz; James K Kirklin; David C Naftel; Daphne T Hsu
Journal:  Circulation       Date:  2012-07-16       Impact factor: 29.690

4.  The role of viral infections in the development of dilated cardiomyopathy.

Authors:  Eniko Tátrai; István Hartyánszky; András Lászik; György Acsády; Péter Sótonyi; Márta Hubay
Journal:  Pathol Oncol Res       Date:  2010-09-18       Impact factor: 3.201

5.  Parvovirus B19 infection associated with dilated cardiomyopathy in patients with previous anthracycline exposure.

Authors:  C J McMahon; H Murchan; T Prendiville; M Burch
Journal:  Pediatr Cardiol       Date:  2007-07-12       Impact factor: 1.655

6.  The Impact of Specific Viruses on Clinical Outcome in Children Presenting with Acute Heart Failure.

Authors:  Maria Giulia Gagliardi; Alessandra Fierabracci; Mara Pilati; Marcello Chinali; Carlo Bassano; Francesca Saura; Isabella Giovannoni; Paola Francalanci
Journal:  Int J Mol Sci       Date:  2016-04-01       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.